NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (Tiziana or the Company), a biotechnology company developing breakthrough immunomodulation therapies via...
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (Tiziana or the Company), a biotechnology company developing breakthrough immunomodulation therapies via...
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-upAll Patients Have Either Stabilized or Improved on Nasal...
Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (Tiziana or the Company), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the American Academy of Neurology
Tiziana Life Sciences Announces Podium Presentation
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (œTiziana or the œCompany), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
Tiziana Life Files New Patent Application for Combination Therapy of anti-CD3
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco